THE STUDY
As pointed out to the authors, they should clarify if the main objective was to develop a risk score for IE or analyse the effect of various biomarkers on prognosis.
It is clear that some of the biomarkers were stored for several years before analysis. A possible effect of storage on measured levels should be taken into account. The use of ROC analysis in appropriate for the study, but should be properly applied.
GENERAL COMMENTS
Reviewer's comments on the article "Cystatin C in a composite risk score for mortality in patients with infective endocarditis: A cohort study" by Bjurman et al.
-The authors use a cohort of 125 patients with infective endocarditis (IE) to assess predictors of short and long-term prognosis. They evaluate different biomarkers in this setting and develop a score with four variables for mortality risk prediction of IE. Strengths of the paper are inclusion of patients with definite IE and examination of several important cardiovascular biomarkers. The availability of biomarkers both at admission and after two weeks is also valuable. I have the following remarks: -The aim of the study should be clear (see abstract and introduction). Was it primarily to develop a risk score in IE or to examine the additive predictive value of CV biomarkers? In the latter case, a recognized risk model should be used as comparator. Development of a scoring system from the rather small cohort in the current study is challenging.
-More details on timing and methods of analysis of biomarkers should be provided. Various biomarkers have been analyzed, of which CRP, NT-proBNP and hsTnT are the ones which are widely available and in use. Many others are not yet, and it would be appropriate to describe when and how these were analyzed.
-Although two-time-points of biomarkers were available, it seems that (apart from CysC) an absolute value, and not the change, was or prognostic significance. Some of the biomarkers (IL-6, CRP, TnT, NT-proBNP) may have rapid changes within hours related to acute illness. Therefore, as supported by the results, values at two weeks may be more reflective of the long-term course of IE. Were changes in biomarker levels also analyzed for other than CysC. For comparison, changes in creatinine/eGFR would be of interest.
-Much of the findings relate to CysC and its effect on prognosis.
Although results from ROC analysis are reported for CysC, it is not clear what the AUC of the suggested risk prediction model is, and to which extent adding CysC improves a model with the other factors (including perhaps eGFR). The overall performance of the model has to be shown, not only after dichotomizing patients (fig 2) -One explanation for the strong impact of CysC is that renal function plays a major role for prognosis in IE. The acute illness and nefrotoxic agents may all impair renal function, which may occur upon previous kidney dysfunction. Creatinine is not a very good marker of kidney function in this setting, especially since creatinine production is prone to decline with the illness and immobility often present with IE w/wo surgery.
Minor comments.
-The authors report that power calculations were made. This is more common in prospective studies and trials. Details on the power calculations should be included if performed (what was the expected difference in mortality, which models were compared etc) Reviewer #1
1. Comment #1: The aim of the study should be clear (see abstract and introduction). Was it primarily to develop a risk score in endocarditis (IE) or to examine the additive predictive value of CV biomarkers? In the latter case, a recognized risk model should be used as comparator.
Reply: Our primary aim was to develop a risk score in infective endocarditis (IE). We have changed the end of the introduction to better reflect this: "Our primary goal was to develop a prognostic score in IE."
2. Comment #2: Development of a scoring system from the rather small cohort in the current study is challenging.
Reply: We agree. However, infective endocarditis is an uncommon condition, which limits the number of patients in most studies. In our cohort, collected during almost 7 years, we managed to include 125 patients is therefore one of the largest single-center study among the studies of prognostic factors that we have found. In addition, we analyzed multiple clinical factors and biomarkers in all patients to optimize the chance to find factors with prognostic implications. Due to the limited number of patients and the fact that this was a single center study underscores the importance to validate the score in other centers before it can be considered for clinical routine. To stress this limitation we have added the following sentence to the "limitations" section in the discussion: " As this was a single center study, our findings must be validated before the risk score can be included in clinical routine."
3. Comment #3: -More details on timing and methods of analysis of biomarkers should be provided. Various biomarkers have been analyzed, of which CRP, NT-proBNP and hsTnT are the ones which are widely available and in use. Many others are not yet, and it would be appropriate to describe when and how these were analyzed.
Reply: All biomarkers were analyzed on frozen serum samples in a single run, which we have now clarified in the Materials and methods: "All biomarkers were analyzed on frozen serum samples in a single run."
4. Comment #4: -Although two-time-points of biomarkers were available, it seems that (apart from Cystatin C) an absolute value, and not the change, was or prognostic significance. Some of the biomarkers (IL-6, CRP, TnT, NT-proBNP) may have rapid changes within hours related to acute illness. Therefore, as supported by the results, values at two weeks may be more reflective of the long-term course of IE. Were changes in biomarker levels also analyzed for other than Cystatin C. For comparison, changes in creatinine/eGFR would be of interest.
Reply: The relative and absolute changes of all biomarkers were evaluated but no significant associations with prognosis were found except for Cystatin C. To clarify this important point we added a sentence about this in the Result section: "The relative and absolute changes of all biomarkers were evaluated but no significant associations with prognosis were found except for Cystatin C."
5. Comment #5: -Much of the findings relate to Cystatin C and its effect on prognosis. Although results from ROC analysis are reported for Cystatin C, it is not clear what the AUC of the suggested risk prediction model is, and to which extent adding Cystatin C improves a model with the other factors (including perhaps eGFR). The overall performance of the model has to be shown, not only after dichotomizing patients (fig 2) .
